Dan Theodorescu | Academic Influence

Dan Theodorescu's AcademicInfluence.com Rankings

Dan Theodorescu

Law

#2553

World Rank

#3179

Historical Rank

Common Law

#111

World Rank

#120

Historical Rank

Download Badge

Law

Dan Theodorescu's Degrees

Bachelors Biology University of California, Berkeley
Doctorate Medicine Stanford University
PhD Molecular Biology Stanford University

Similar Degrees You Can Earn

Best Online Bachelor's in Biology 2025

Why Is Dan Theodorescu Influential?

(Suggest an Edit or Addition)

According to Wikipedia, Dan Theodorescu is an American physician and academic. He is the Director of the Samuel Oschin Comprehensive Cancer Institute at the Cedars-Sinai Medical Center and leader of Cedars-Sinai CANCER. From 2010 until 2018, Theodorescu was Director of the University of Colorado Cancer Center and a professor of Surgery-Urology. He has been appointed Paul Mellon Chair at the University of Virginia and Paul Bunn Chair and Distinguished University Professor at the University of Colorado.

(See a Problem?)

Dan Theodorescu's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

TERT promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal (2013) (1148)
Frequent mutations of chromatin remodeling genes in transitional cell carcinoma of the bladder (2011) (664)
Naturally Occurring Human Urinary Peptides for Use in Diagnosis of Chronic Kidney Disease* (2010) (425)
Whole-genome and whole-exome sequencing of bladder cancer identifies frequent alterations in genes involved in sister chromatid cohesion and segregation (2013) (423)
Discovery and validation of new protein biomarkers for urothelial cancer: a prospective analysis. (2006) (396)
Metastasis: a therapeutic target for cancer (2008) (320)
The multiMiR R package and database: integration of microRNA–target interactions along with their disease and drug associations (2014) (311)
Clinical proteomics: A need to define the field and to begin to set adequate standards (2007) (303)
Recommendations for Biomarker Identification and Qualification in Clinical Proteomics (2010) (298)
A strategy for predicting the chemosensitivity of human cancers and its application to drug discovery (2007) (289)
Cancer incidence after localized therapy for prostate cancer (2006) (258)
TERT promoter mutations and telomerase reactivation in urothelial cancer (2015) (257)
RhoGDI2 is an invasion and metastasis suppressor gene in human cancer. (2002) (235)
Cellular disposal of miR23b by RAB27-dependent exosome release is linked to acquisition of metastatic properties. (2014) (226)
Fibroblast cell interactions with human melanoma cells affect tumor cell growth as a function of tumor progression. (1991) (214)
Molecular cloning and characterization of a lysophosphatidic acid receptor, Edg-7, expressed in prostate. (2000) (204)
Isolation and identification of potential urinary microparticle biomarkers of bladder cancer. (2008) (199)
CE‐MS analysis of the human urinary proteome for biomarker discovery and disease diagnostics (2008) (197)
TGF-beta 1 is an autocrine-negative growth regulator of human colon carcinoma FET cells in vivo as revealed by transfection of an antisense expression vector (1992) (196)
Advances in bladder cancer biology and therapy (2020) (191)
Biomarker discovery by CE‐MS enables sequence analysis via MS/MS with platform‐independent separation (2006) (190)
Learning therapeutic lessons from metastasis suppressor proteins (2009) (180)
Adenosine A2B Receptor Blockade Slows Growth of Bladder and Breast Tumors (2012) (172)
ICUD-EAU International Consultation on Bladder Cancer 2012: Chemotherapy for urothelial carcinoma-neoadjuvant and adjuvant settings. (2013) (165)
Mutation of the TERT promoter, switch to active chromatin, and monoallelic TERT expression in multiple cancers (2015) (164)
Prostatourethral‐rectal fistula after prostate brachytherapy (2000) (161)
Reduced Expression of Metastasis Suppressor RhoGDI2 Is Associated with Decreased Survival for Patients with Bladder Cancer (2004) (160)
Pilot study of capillary electrophoresis coupled to mass spectrometry as a tool to define potential prostate cancer biomarkers in urine (2005) (155)
Outcomes of initial surveillance of invasive squamous cell carcinoma of the penis and negative nodes. (1996) (147)
Overlapping gene expression profiles of cell migration and tumor invasion in human bladder cancer identify metallothionein 1E and nicotinamide N-methyltransferase as novel regulators of cell migration (2008) (146)
p53, bcl-2 and retinoblastoma proteins as long-term prognostic markers in localized carcinoma of the prostate. (1997) (146)
Discovery and validation of urinary biomarkers for prostate cancer (2008) (146)
Frequent truncating mutations of STAG2 in bladder cancer (2013) (146)
The metastasis-associated gene CD24 is regulated by Ral GTPase and is a mediator of cell proliferation and survival in human cancer. (2006) (143)
Cell density mediated pericellular hypoxia leads to induction of HIF-1α via nitric oxide and Ras/MAP kinase mediated signaling pathways (2001) (140)
A 20-gene model for molecular nodal staging of bladder cancer: development and prospective assessment. (2011) (133)
Metastasis Suppressor Proteins: Discovery, Molecular Mechanisms, and Clinical Application (2006) (130)
Angiogenesis and prostate cancer tumor growth (2004) (129)
RalA and RalB: antagonistic relatives in cancer cell migration. (2005) (127)
The relationship of BRMS1 and RhoGDI2 gene expression to metastatic potential in lineage related human bladder cancer cell lines (2004) (126)
RhoGDI2 suppresses lung metastasis in mice by reducing tumor versican expression and macrophage infiltration. (2012) (125)
Cathepsin D and chromogranin A as predictors of long term disease specific survival after radical prostatectomy for localized carcinoma of the prostate (1997) (120)
Precision medicine for urothelial bladder cancer: update on tumour genomics and immunotherapy (2018) (120)
Discovery and characterization of small molecules that target the GTPase Ral (2014) (120)
Sensitivity to Epidermal Growth Factor Receptor Inhibitor Requires E-Cadherin Expression in Urothelial Carcinoma Cells (2008) (114)
CD24 offers a therapeutic target for control of bladder cancer metastasis based on a requirement for lung colonization. (2011) (112)
Overexpression of normal and mutated forms of HRAS induces orthotopic bladder invasion in a human transitional cell carcinoma. (1990) (110)
Endothelin axis is a target of the lung metastasis suppressor gene RhoGDI2. (2005) (110)
Gleason scores of prostate biopsy and radical prostatectomy specimens over the past 10 years (2002) (109)
Identification and Validation of Urinary Biomarkers for Differential Diagnosis and Evaluation of Therapeutic Intervention in Anti-neutrophil Cytoplasmic Antibody-associated Vasculitis* (2009) (105)
Tumor endothelin-1 enhances metastatic colonization of the lung in mouse xenograft models of bladder cancer. (2011) (104)
Alternative medicine use in patients with localized prostate carcinoma treated with curative intent (1999) (103)
CD24 is an effector of HIF-1-driven primary tumor growth and metastasis. (2012) (100)
Cytoplasmic p27 promotes epithelial–mesenchymal transition and tumor metastasis via STAT3-mediated Twist1 upregulation (2015) (99)
Radical cystectomy with ileal conduit diversion: early prospective evaluation of the impact of robotic assistance (2006) (98)
The COXEN principle: translating signatures of in vitro chemosensitivity into tools for clinical outcome prediction and drug discovery in cancer. (2010) (98)
Prediction of Muscle-invasive Bladder Cancer Using Urinary Proteomics (2009) (96)
The UBC-40 Urothelial Bladder Cancer cell line index: a genomic resource for functional studies (2015) (96)
Concurrent Alterations in TERT, KDM6A, and the BRCA Pathway in Bladder Cancer (2014) (94)
Why patients choose prostatectomy or brachytherapy for localized prostate cancer: results of a descriptive survey. (2003) (93)
miRNAs associated with chemo-sensitivity in cell lines and in advanced bladder cancer (2012) (93)
The role of Ras superfamily proteins in bladder cancer progression. (2003) (92)
Profiling the Evolution of Human Metastatic Bladder Cancer (2004) (92)
Multi-Gene Expression Predictors of Single Drug Responses to Adjuvant Chemotherapy in Ovarian Carcinoma: Predicting Platinum Resistance (2012) (90)
Cancer cryotherapy: evolution and biology. (2004) (90)
Ras superfamily monomeric G proteins in carcinoma cell motility. (2003) (87)
Loss of the Urothelial Differentiation Marker FOXA1 Is Associated with High Grade, Late Stage Bladder Cancer and Increased Tumor Proliferation (2012) (85)
Quality-of-life comparison of radical prostatectomy and interstitial brachytherapy in the treatment of clinically localized prostate cancer. (2000) (84)
PTEN can inhibit in vitro organotypic and in vivo orthotopic invasion of human bladder cancer cells even in the absence of its lipid phosphatase activity (2004) (84)
Genetic and phenotypic changes associated with the acquisition of tumorigenicity in human bladder cancer (2000) (83)
Src and caveolin-1 reciprocally regulate metastasis via a common downstream signaling pathway in bladder cancer. (2011) (83)
Loss of SPARC in bladder cancer enhances carcinogenesis and progression. (2013) (83)
The role of Ral A in epidermal growth factor receptor-regulated cell motility. (2002) (82)
Mammalian target of rapamycin (mTOR) regulates cellular proliferation and tumor growth in urothelial carcinoma. (2010) (81)
Clinical trials with endothelin receptor antagonists: what went wrong and where can we improve? (2012) (81)
Prospective Comparison of Clinical and Genomic Multivariate Predictors of Response to Neoadjuvant Chemotherapy in Breast Cancer (2010) (81)
RhoGDI signaling provides targets for cancer therapy. (2010) (80)
Development and Validation of Urine-based Peptide Biomarker Panels for Detecting Bladder Cancer in a Multi-center Study (2016) (79)
Concordant gene expression signatures predict clinical outcomes of cancer patients undergoing systemic therapy. (2009) (79)
CD24 expression is important in male urothelial tumorigenesis and metastasis in mice and is androgen regulated (2012) (78)
Impact of second opinion pathology in the definitive management of patients with bladder carcinoma (2001) (78)
Expression of Ral GTPases, Their Effectors, and Activators in Human Bladder Cancer (2007) (76)
A Carcinogen-induced Mouse Model Recapitulates the Molecular Alterations of Human Muscle Invasive Bladder Cancer (2017) (75)
RAL GTPases: Biology and Potential as Therapeutic Targets in Cancer (2018) (75)
Extensive multi‐organ metastasis following orthotopic onplantation of histologically‐intact human bladder carcinoma tissue in nude mice (1991) (74)
Targeting DDR2 enhances tumor response to anti–PD-1 immunotherapy (2019) (74)
Molecular analysis of urothelial cancer cell lines for modeling tumor biology and drug response (2016) (73)
Src phosphorylation of RhoGDI2 regulates its metastasis suppressor function (2009) (72)
Rho GDP dissociation inhibitor 2 suppresses metastasis via unconventional regulation of RhoGTPases. (2009) (71)
Assessment of Luminal and Basal Phenotypes in Bladder Cancer (2020) (68)
Discovery and validation of urinary biomarkers for detection of renal cell carcinoma. (2014) (66)
Morbidity of modified prophylactic inguinal lymphadenectomy for squamous cell carcinoma of the penis. (2002) (66)
Translation Initiation Factor eIF3b Expression in Human Cancer and Its Role in Tumor Growth and Lung Colonization (2013) (65)
RalBP1 is necessary for metastasis of human cancer cell lines. (2010) (64)
Clinical opportunities and challenges in targeting tumour dormancy (2013) (64)
Inhibition of the CCL2 receptor, CCR2, enhances tumor response to immune checkpoint therapy (2020) (63)
Depletion of major vault protein increases doxorubicin sensitivity and nuclear accumulation and disrupts its sequestration in lysosomes (2007) (63)
Molecular credentialing of rodent bladder carcinogenesis models. (2008) (61)
Neuromedin U is regulated by the metastasis suppressor RhoGDI2 and is a novel promoter of tumor formation, lung metastasis and cancer cachexia (2007) (61)
Pilot Experience With Real-Time Ultrasound Guided Percutaneous Renal Mass Cryoablation (2004) (61)
Prospective assessment of voiding and sexual function after treatment for localized prostate carcinoma (2001) (60)
Bladder cancer: narrowing the gap between evidence and practice. (2009) (58)
Transforming growth factor beta 1 (TGF beta 1) is an autocrine positive regulator of colon carcinoma U9 cells in vivo as shown by transfection of a TGF beta 1 antisense expression plasmid. (1995) (58)
Functional genomic comparison of lineage-related human bladder cancer cell lines with differing tumorigenic and metastatic potentials by spectral karyotyping, comparative genomic hybridization, and a novel method of positional expression profiling. (2002) (57)
The role of SPARC in the TRAMP model of prostate carcinogenesis and progression (2009) (56)
Mass spectrometry based proteomics in urine biomarker discovery (2007) (56)
Relationship between HLA class I antigen processing machinery component expression and the clinicopathologic characteristics of bladder carcinomas (2010) (55)
Utilizing the molecular gateway: the path to personalized cancer management. (2009) (55)
Targeting glycogen metabolism in bladder cancer (2015) (54)
Phosphorylation of RalB is important for bladder cancer cell growth and metastasis. (2010) (54)
Urinary function after radical prostatectomy: a comparison of the retropubic and perineal approaches. (1999) (53)
Focal adhesion kinase, Rap1, and transcriptional induction of vascular endothelial growth factor. (2000) (52)
Cdc6 and cyclin E2 are PTEN-regulated genes associated with human prostate cancer metastasis. (2009) (51)
Prediction of drug combination chemosensitivity in human bladder cancer (2007) (51)
Ha-ras induction of the invasive phenotype results in up-regulation of epidermal growth factor receptors and altered responsiveness to epidermal growth factor in human papillary transitional cell carcinoma cells. (1991) (49)
An Osteopontin/CD44 Axis in RhoGDI2-Mediated Metastasis Suppression. (2016) (48)
Surgical and postoperative factors affecting length of hospital stay after radical prostatectomy (2000) (48)
Staging pelvic lymphadenectomy for localized carcinoma of the prostate: a comparison of 3 surgical techniques. (1997) (48)
Motivations and influences on the use of complementary medicine in patients with localized prostate cancer treated with curative intent: results of a pilot study (2003) (48)
Neonatal pharyngoesophageal perforation mimicking esophageal atresia: clues to diagnosis. (1987) (47)
Differential requirement for focal adhesion kinase signaling in cancer progression in the transgenic adenocarcinoma of mouse prostate model (2009) (47)
Molecular genesis of non-muscle-invasive urothelial carcinoma (NMIUC) (2010) (46)
Determinants of long‐term quality of life and voiding function of patients treated with radical prostatectomy or permanent brachytherapy for prostate cancer (2004) (45)
Renal transplant recipients and patients with end stage renal disease present with more advanced bladder cancer. (2009) (45)
Inhibition of human bladder cancer cell motility by genistein is dependent on epidermal growth factor receptor but not p21ras gene expression (1998) (45)
A Cell of Origin Gene Signature Indicates Human Bladder Cancer Has Distinct Cellular Progenitors (2014) (44)
Profiling bladder cancer organ site-specific metastasis identifies LAMC2 as a novel biomarker of hematogenous dissemination. (2009) (43)
Complementary and alternative medicine modality use and beliefs among African American prostate cancer survivors. (2007) (43)
Biomarkers for prognosis and treatment selection in advanced bladder cancer patients (2011) (42)
Epidermal growth factor receptor-regulated human bladder cancer motility is in part a phosphatidylinositol 3-kinase-mediated process. (1998) (42)
Use of the aromatase inhibitor anastrozole in the treatment of patients with advanced prostate carcinoma (2001) (41)
Rho proteins in cell migration and metastasis. (2005) (41)
Angiogenesis in Prostate Cancer: Biology and Therapeutic Opportunities (2004) (41)
The effect of sampling more cores on the predictive accuracy of pathological grade and tumour distribution in the prostate biopsy (2004) (41)
Altered Expression of Transmembrane Mucins, MUC1 and MUC4, in Bladder Cancer: Pathological Implications in Diagnosis (2014) (40)
Molecular pathogenesis of urothelial bladder cancer. (2003) (40)
Loss of SPARC in bladder cancer enhances carcinogenesis and progression (Journal of Clinical Investigation (2013) 123, 2 (751-766) DOI: 10.1172/JCI64782) (2013) (40)
Longitudinal comparison of sexual function after 3-dimensional conformal radiation therapy or prostate brachytherapy. (2002) (39)
Systematic Review: Characteristics and Preclinical Uses of Bladder Cancer Cell Lines (2018) (39)
The Hautmann neobladder with a chimney: a versatile modification. (1997) (39)
Contributions of KRAS and RAL in Non–Small-Cell Lung Cancer Growth and Progression (2013) (38)
Quality of life comparison of radical prostatectomy and interstitial brachytherapy in the treatment of clinically localized prostate cancer (1999) (38)
RhoGDI2: a new metastasis suppressor gene: discovery and clinical translation. (2007) (37)
The role of PTEN in prostate cancer cell tropism to the bone micro-environment. (2007) (36)
Urethral replacement with vascularized tunica vaginalis: defining the optimal form of use. (1998) (36)
Transcriptional signatures of Ral GTPase are associated with aggressive clinicopathologic characteristics in human cancer. (2012) (36)
Role in tumor growth of a glycogen debranching enzyme lost in glycogen storage disease. (2014) (36)
RhoGDI2 suppresses bladder cancer metastasis via reduction of inflammation in the tumor microenvironment (2012) (35)
Thymectomy in Juvenile Myasthenia Gravis (1990) (35)
Family Interactions Among African American Prostate Cancer Survivors (2008) (35)
Molecular determination of surgical margins using fossa biopsies at radical prostatectomy. (1999) (35)
Prospective evaluation of the prognostic relevance of molecular staging for urothelial carcinoma (2006) (34)
Importance of orthotopic transplantation procedures in assessing the effects of transfected genes on human tumor growth and metastasis (1991) (34)
Dominance of metastatically competent cells in primary murine breast neoplasms is necessary for distant metastatic spread (1991) (34)
RalA controls glucose homeostasis by regulating glucose uptake in brown fat (2018) (34)
In vitro transcriptomic prediction of hepatotoxicity for early drug discovery. (2011) (33)
Case-matched comparison of contemporary radiation therapy to surgery in patients with locally advanced prostate cancer. (2006) (33)
Restoration of PTEN expression alters the sensitivity of prostate cancer cells to EGFR inhibitors (2008) (32)
Molecular determination of perivesical and lymph node metastasis after radical cystectomy for urothelial carcinoma of the bladder. (2001) (32)
Determinants of Resistance to Checkpoint Inhibitors (2020) (32)
An N-Cadherin 2 expressing epithelial cell subpopulation predicts response to surgery, chemotherapy and immunotherapy in bladder cancer (2021) (31)
An 800-kb region of deletion at 13q14 in human prostate and other carcinomas. (2001) (31)
A Randomized Phase II Study of Coexpression Extrapolation (COXEN) with Neoadjuvant Chemotherapy for Bladder Cancer (SWOG S1314; NCT02177695) (2021) (31)
GON4L Drives Cancer Growth through a YY1-Androgen Receptor-CD24 Axis. (2016) (31)
Metastatic cells are preferentially vulnerable to lysosomal inhibition (2018) (31)
Preclinical Drug Development Must Consider the Impact on Metastasis (2009) (31)
Rap2 regulates androgen sensitivity in human prostate cancer cells (2007) (30)
Use of yeast chemigenomics and COXEN informatics in preclinical evaluation of anticancer agents. (2011) (30)
Comparison of global versus epidermal growth factor receptor pathway profiling for prediction of lapatinib sensitivity in bladder cancer. (2009) (30)
Functional Impact of Chromatin Remodeling Gene Mutations and Predictive Signature for Therapeutic Response in Bladder Cancer (2017) (30)
The faces and friends of RhoGDI2 (2012) (29)
Conditional expression of PTEN alters the androgen responsiveness of prostate cancer cells (2006) (29)
The RAS-RAL axis in cancer: evidence for mutation-specific selectivity in non-small cell lung cancer (2015) (28)
The relationship of palliative transurethral resection of the prostate with disease progression in patients with prostate cancer (2010) (28)
Status of robotic cystectomy in 2005 (2006) (28)
Reduction of TGF‐beta activity abrogates growth promoting tumor cell‐cell interactions in vivo (1991) (27)
Novel neoadjuvant therapy paradigms for bladder cancer: results from the National Cancer Center Institute Forum. (2014) (26)
Integrin Agonists as Adjuvants in Chemotherapy for Melanoma (2008) (26)
Early prostate-specific antigen failure following radical perineal versus retropubic prostatectomy: the importance of seminal vesicle excision. (1998) (26)
A Quantitative Proteomic Analysis Uncovers the Relevance of CUL3 in Bladder Cancer Aggressiveness (2013) (26)
Gene profiling and promoter reporter assays: Novel tools for comparing the biological effects of botanical extracts on human prostate cancer cells and understanding their mechanisms of action (2003) (26)
Collaboration of RON and epidermal growth factor receptor in human bladder carcinogenesis. (2006) (26)
Pathways of metastasis suppression in bladder cancer (2009) (26)
Transmembrane motility assay of transiently transfected cells by fluorescent cell counting and luciferase measurement. (2000) (26)
Permissive role of endothelin receptors in tumor metastasis. (2012) (25)
Statistical identification of differentially labeled peptides from liquid chromatography tandem mass spectrometry (2007) (25)
SWOG S1314: A randomized phase II study of co-expression extrapolation (COXEN) with neoadjuvant chemotherapy for localized, muscle-invasive bladder cancer. (2019) (25)
Robust Prognostic Gene Expression Signatures in Bladder Cancer and Lung Adenocarcinoma Depend on Cell Cycle Related Genes (2014) (25)
The Ral GTPase pathway in metastatic bladder cancer: key mediator and therapeutic target. (2009) (24)
A novel model to identify interaction partners of the PTEN tumor suppressor gene in human bladder cancer. (2007) (24)
Expression profiling of Ral-depleted bladder cancer cells identifies RREB-1 as a novel transcriptional Ral effector (2007) (24)
Cyclophilin B expression is associated with in vitro radioresistance and clinical outcome after radiotherapy. (2011) (24)
The Role of Vascular Endothelial Growth Factor in the Tissue Specific in Vivo Growth of Prostate Cancer Cells (2001) (24)
A whole-genome RNAi screen uncovers a novel role for human potassium channels in cell killing by the parasite Entamoeba histolytica (2015) (24)
The impact of prostate volume following neoadjuvant androgen deprivation on quality of life and voiding symptoms in patients undergoing permanent prostate brachytherapy. (2003) (23)
A framework to select clinically relevant cancer cell lines for investigation by establishing their molecular similarity with primary human cancers. (2011) (23)
gamma-Glutamyl transpeptidase in normal and neoplastic prostate glands. (1997) (23)
RREB1 transcription factor splice variants in urologic cancer. (2011) (23)
Invasion and metastasis models for studying RhoGDI2 in bladder cancer. (2008) (23)
Loss of Glycogen Debranching Enzyme AGL Drives Bladder Tumor Growth via Induction of Hyaluronic Acid Synthesis (2015) (22)
Genoproteomic mining of urothelial cancer suggests {gamma}-glutamyl hydrolase and diazepam-binding inhibitor as putative urinary markers of outcome after chemotherapy. (2009) (22)
Challenges of using mass spectrometry as a bladder cancer biomarker discovery platform (2008) (21)
Manipulation of gene expression by an ecdysone-inducible gene switch in tumor xenografts (2001) (21)
Orthotopic Neobladder Following Cystectomy: Indications, Management, and Outcomes (2001) (21)
CD44 and RHAMM are essential for rapid growth of bladder cancer driven by loss of Glycogen Debranching Enzyme (AGL) (2016) (21)
Permanent interstitial brachytherapy for prostate cancer: a current review (2003) (21)
Evaluation of urinary continence and voiding function: early results in men with neo-urethral modification of the Hautmann orthotopic neobladder. (2002) (21)
Combination Antiangiogenic and Androgen Deprivation Therapy for Prostate Cancer (2004) (20)
PKCα phosphorylation of RhoGDI2 at Ser 31 disrupts interactions with Rac1 and decreases GDI activity (2012) (20)
Adrenal Tumor with Caval Extension: Case Report and Review of the Literature (2002) (20)
Patient Mutation Directed shRNA Screen Uncovers Novel Bladder Tumor Growth Suppressors (2015) (20)
Assessment of roles for the Rho-specific guanine nucleotide dissociation inhibitor Ly-GDI in platelet function: a spatial systems approach. (2017) (20)
New and promising strategies in the management of bladder cancer. (2015) (19)
A novel method for gene expression mapping of metastatic competence in human bladder cancer. (2006) (19)
Perioperative costs and charges of prostate brachytherapy and prostatectomy. (2002) (19)
Cloning and overexpression of TGF-beta 1 cDNA in a mammary adenocarcinoma: in vitro and in vivo effects. (1991) (18)
Nuclear CD24 Drives Tumor Growth and Is Predictive of Poor Patient Prognosis. (2017) (18)
Predicting tumor outcomes in urothelial bladder carcinoma: turning pathways into clinical biomarkers of prognosis (2008) (17)
Molecular therapeutics in prostate cancer. (2003) (17)
Terahertz spectroscopic characterization of cancer cells (2005) (17)
Androgen Receptor Regulates CD44 Expression in Bladder Cancer (2021) (16)
Impact of a novel neoadjuvant and adjuvant hormone‐deprivation approach on quality of life, voiding function, and sexual function after prostate brachytherapy (2003) (16)
RhoC Is an Unexpected Target of RhoGDI2 in Prevention of Lung Colonization of Bladder Cancer (2014) (16)
Clinical Decision Making in Surveillance of Non-Muscle-Invasive Bladder Cancer: The Evolving Roles of Urinary Cytology and Molecular Markers. (2017) (15)
Mass spectroscopic phosphoprotein mapping of Ral binding protein 1 (RalBP1/Rip1/RLIP76). (2007) (15)
Pharmacogenomics in bladder cancer. (2014) (14)
A prospective pilot evaluation of urinary and immunohistochemical markers as predictors of clinical stage of urothelial carcinoma of the bladder (2000) (14)
Targetable Pathways in Advanced Bladder Cancer: FGFR Signaling (2021) (13)
TRIM28 is a transcriptional activator of the mutant TERT promoter in human bladder cancer (2021) (13)
Prognostic Markers in Localized Prostate Cancer: From Microscopes to Molecules (1998) (13)
A 20 gene model for predicting nodal involvement in bladder cancer patients with muscle invasive tumors (2011) (12)
Pharmacogenomics: Biomarker-Directed Therapy for Bladder Cancer. (2016) (12)
A Rho GDP Dissociation Inhibitor Produced by Apoptotic T-Cells Inhibits Growth of Mycobacterium tuberculosis (2015) (12)
Secreted Protein Acidic and Rich in Cysteine (Sparc) in Cancer (2013) (12)
Cell death-induced immunogenicity enhances chemoimmunotherapeutic response by converting immune-excluded into T-cell inflamed bladder tumors (2022) (12)
Tumor control outcomes of patients treated with trimodality therapy for locally advanced prostate cancer. (2005) (11)
Retrospective Analysis of Survival Improvement by Molecular Biomarker-Based Personalized Chemotherapy for Recurrent Ovarian Cancer (2014) (11)
The Role of Transcription Factor YY1 in the Biology of Cancer. (2017) (11)
Urothelial-to-Neural Plasticity Drives Progression to Small Cell Bladder Cancer (2020) (10)
When is a negative lymph node really negative? Molecular tools for the detection of lymph node metastasis from urological cancer. (2004) (10)
Personalized medicine in advanced urothelial cancer: when to treat, how to treat and who to treat. (2013) (10)
Prospective outcomes associated with migration from preoperative to intraoperative planned brachytherapy: a single center report. (2004) (10)
Undetectable prostate specific antigen at 6–12 months (2005) (10)
Multimodality radiotherapy and androgen ablation in the treatment of clinically localized prostate cancer: early results in high risk patients (2002) (10)
576: Combination Antiangiogenic and Androgen Deprivation Therapy for Prostate Cancer: A Promising Therapeutic Approach (2005) (10)
Telomerase in bladder cancer: back to a better future? (2014) (10)
Molecular markers of prognosis and novel therapeutic strategies for urothelial cell carcinomas (2006) (9)
Improving Anti-PD-1/PD-L1 Therapy for Localized Bladder Cancer (2021) (9)
Surgery or radiation: what is the optimal management for locally advanced prostate cancer? (2005) (9)
Decade in review—bladder cancer: International progress: from cytology to genomics (2014) (9)
Synthesis of novel Ral inhibitors: An in vitro and in vivo study. (2016) (9)
Atypical small acinar proliferation: biopsy artefact or distinct pathological entity? (2007) (9)
A gene expression ratio-based diagnostic test for bladder cancer (2009) (9)
Summary of the 8th Annual Bladder Cancer Think Tank: Collaborating to move research forward. (2015) (8)
Robot-Assisted Radical Cystectomy in the Management of Bladder Cancer (2006) (8)
CD44: A metastasis driver and therapeutic target (2016) (8)
Clinical Utility of Olaparib in the Treatment of Metastatic Castration-Resistant Prostate Cancer: A Review of Current Evidence and Patient Selection (2021) (8)
Molecular markers in transitional cell carcinoma of the bladder: New insights into mechanisms and prognosis (2008) (8)
Looking forward, looking back—10 years in urology (2014) (8)
High-performance detection of somatic D-loop mutation in urothelial cell carcinoma patients by polymorphism ratio sequencing (2016) (7)
Role of Bladder Cancer Metabolic Reprogramming in the Effectiveness of Immunotherapy (2021) (7)
Pharmacogenomic considerations in the treatment of muscle-invasive bladder cancer. (2017) (7)
Health‐related quality of life after prostate brachytherapy (2004) (7)
A Gene Expression Signature Predicts Bladder Cancer Cell Line Sensitivity to EGFR Inhibition (2018) (6)
Prostate specific antigen kinetics at tumor recurrence after radical prostatectomy do not suggest a worse disease prognosis in black men. (2001) (6)
Cryotherapy for prostate cancer: what we know, what we need to know. (2008) (6)
Prospective evaluation of the effect of ionizing radiation on the bladder tumor-associated (BTA) urine test. (1999) (6)
Glycogen debranching enzyme (AGL) is a novel regulator of non-small cell lung cancer growth (2018) (6)
Commentary on genetic prognostic markers for transitional cell carcinoma of the bladder: from microscopes to molecules. (1996) (6)
Genomancy: predicting tumour response to cancer therapy based on the oracle of genetics (2009) (6)
Brachytherapy for prostate cancer: follow-up and management of treatment failures. (2003) (6)
TGF-β gene expression depends on tissue architecture (1993) (5)
FimH confers mannose-targeting ability to Bacillus Calmette-Guerin for improved immunotherapy in bladder cancer (2022) (5)
The Prognostic Value of Cell Cycle Gene Expression Signatures in Muscle Invasive, High-Grade Bladder Cancer (2015) (5)
Tumor Cell Subpopulation Interactions Mediated by Transforming Growth Factor β May Contribute to Clonal Dominance of Metastatically Competent Cells in Primary Tumors (1990) (5)
Editorial (2015) (5)
A müllerian duct cyst presenting as a large complex pelvic mass. (1997) (5)
Brachytherapy of prostate cancer after colectomy for colorectal cancer: pilot experience. (2005) (4)
Erratum to: The UBC-40 Urothelial Bladder Cancer cell line index: a genomic resource for functional studies (2016) (4)
Immunotherapy of High Risk Non-Muscle Invasive Bladder Cancer (2021) (4)
The promise of gene‐expression analysis in bladder cancer: a clinician's guide (2005) (4)
Elucidating the role of Agl in bladder carcinogenesis by generation and characterization of genetically engineered mice (2018) (4)
The origin of bladder cancer from mucosal field effects (2021) (4)
Bladder cancer in 2011: The dawn of personalized medicine (2012) (4)
The dynamic roles of the bladder tumour microenvironment (2022) (4)
Regulation of phosphatase homologue of tensin protein expression by bone morphogenetic proteins in prostate epithelial cells (2010) (4)
Association of molecular subtypes with pathologic response in a phase II study of co-expression extrapolation (COXEN) with neoadjuvant chemotherapy (NAC) for localized, muscle-invasive bladder cancer (SWOG S1314; NCT02177695). (2020) (4)
TGF-beta gene expression depends on tissue architecture. (1993) (4)
Lack of influence of c-Ha-ras expression on the drug sensitivity of human bladder cancer histocultured in three-dimensions. (1993) (4)
Follow-up strategies and management of recurrence in urologic oncology (2003) (3)
Erratum to: The UBC-40 Urothelial Bladder Cancer Cell Line Index: a genomic resource for functional studies (2015) (3)
Focal Adhesion Kinase , Rap 1 , and Transcriptional Induction of Vascular Endothelial Growth Factor (3)
Unusual case of non-exophytic invasive penile squamous cell cancer arising from a chronic sinus tract. (1999) (3)
Short Communication Genoproteomic Mining of Urothelial Cancer Suggests -Glutamyl Hydrolase and Diazepam-Binding Inhibitor as Putative Urinary Markers of Outcome after Chemotherapy (2009) (3)
The intestinoprostatic capsule anastomosis: functional and anatomic results in a canine model. (1992) (3)
Does saturation biopsy improve prostate cancer detection? (2006) (3)
Development of novel aptamer-based targeted chemotherapy for bladder cancer. (2022) (3)
COXEN prediction of antineoplastic drug sensitivity in bladder cancer patients. (2015) (3)
Drug Selection in the Genomic Age: Application of the Coexpression Extrapolation Principle for Drug Repositioning in Cancer Therapy. (2015) (3)
Chronic adult renal vein thrombosis: Two unusual cases and a review of the literature (2007) (3)
Editorial: Prostate Cancer–Our Patients' Questions (1996) (3)
Sex-biased adaptive immune regulation in cancer development and therapy (2022) (3)
Advances in bladder cancer biology and therapy (2020) (2)
Using Cell Lines To Guide Neoadjuvant Therapy in Bladder Cancer: COXEN and SWOG S1314. (2022) (2)
Drugging the Ral GTPase (2015) (2)
The impact of the social construct of race on outcomes among bacille Calmette‐Guérin‐treated patients with high‐risk non‐muscle–invasive bladder cancer in an equal‐access setting (2021) (2)
Rare bladder tumors: caveat emptor. (2010) (2)
Molecular Targeted Therapy of Bladder Cancer (2018) (2)
Bladder cancer: Bladder preservation—learning what we don't know (2014) (2)
Prostatourethral-rectal fistula after prostate brachytherapy: Incidence and risk factors (2000) (2)
SWOG S1314: A randomized phase II study of co-expression extrapolation (COXEN) with neoadjuvant chemotherapy for localized, muscle-invasive bladder cancer with overall survival follow up. (2022) (2)
Phosphoinositide signaling in urological disease. (2003) (2)
EDITORIAL: PHOSPHOINOSITIDE SIGNALING IN UROLOGICAL DISEASE (2003) (2)
1036: Undetectable PSA at 6-12 Months: A New Marker for Early Success in Hormonally Treated Patients Following Prostate Brachytherapy (2005) (2)
Words of wisdom. Re: Phase III study of molecularly targeted adjuvant therapy in locally advanced urothelial cancer of the bladder based on p53 status. (2012) (2)
Characterizing molecular subtypes of high-risk non-muscle-invasive bladder cancer in African American patients. (2022) (2)
Molecular markers: their role as prognostic indicators for bladder cancer (1997) (2)
Unusual case of recurrent low‐grade invasive and endophytic squamous cell carcinoma of the penis (2004) (1)
CD44 and RHAMM are essential for rapid growth of bladder cancer driven by loss of Glycogen Debranching Enzyme (AGL) (2016) (1)
PATIENTS WITH RENAL TRANSPLANT OR END-STAGE RENAL DISEASE PRESENT WITH MORE ADVANCED BLADDER CANCER (2008) (1)
A Festschrift in Honor of Edward M. Messing, MD, FACS (2018) (1)
The Potential of Combination Therapies and Patient Stratification to Improve CCR2 Inhibition Therapeutics (2021) (1)
NPEPPS regulates intracellular import and sensitivity to cisplatin by interaction with volume-regulated anion channels (2022) (1)
Discoidin domain receptor-driven gene signatures as markers of patient response to anti-PD-L1 immune checkpoint therapy. (2022) (1)
Discovery and characterization of small molecules that target the Ral GTPase (2014) (1)
One step closer to targeting RAS (2015) (1)
952: Marcks Downregulation is Associated with Loss of Metastatic Phenotype Following Transfection of the Metastasis Suppressor Gene RhoGDI2 in the Metastatic Human Bladder Cancer Cell Line T24T (2004) (1)
Abstract 50: An informatic approach to rational selection of cell lines modeling complex clinicopathologic phenotypes based on gene expression: The COXEN algorithm (2011) (1)
Radiation for prostate cancer issue (2003) (1)
COMPARISON OF QUALITY OF LIFE IN PATIENTS TREATED BY EITHER RADICAL PROSTATECTOMY OR BRACHYTHERAPY FOR CLINICALLY LOCALIZED PROSTATE CANCER (1999) (1)
Abstract 4783: Novel molecular markers of bladder cancer progression identified by global chromatin profiling (2015) (1)
CULTURAL BELIEFS AND ATTITUDES OF AFRICAN AMERICAN PROSTATE CANCER SURVIVORS (2011) (1)
Re: Postoperative Nomogram Predicting Risk of Recurrence after Radical Cystectomy for Bladder Cancer (2007) (1)
Biology of Human Tumors Concurrent Alterations in TERT , KDM 6 A , and the BRCA Pathway in Bladder Cancer (2014) (1)
Frequent truncating mutations of the cohesin complex gene STAG2 in urothelial carcinoma of the bladder. (2014) (1)
Abstract 3387: Secreted exosomes from cultured bladder cells are enriched for distinct miRNAs detected in circulation of metastatic bladder cancer patients (2012) (1)
Mechanism of Sex Differences in Bladder Cancer: Evident and Elusive Sex-biasing Factors (2022) (1)
Metastatic melanoma presenting as an ileal conduit filling defect. (2001) (1)
Targeted Long-Read Bisulfite Sequencing Identifies Differences in the TERT Promoter Methylation Profiles between TERT Wild-Type and TERT Mutant Cancer Cells (2022) (1)
Biology and Molecular Aspects of Development and Progression of Bladder Cancer (2001) (1)
Altered growth and spontaneous transformation of cells cultured from v-jun transgenic mice recapitulate wound-induced multistage tumorigenesis. (1993) (1)
Perspectives on personalized cancer care. (2012) (1)
PROSPECTIVE ASSESSMENT OF VOIDING FUNCTION AFTER TREATMENT FOR LOCALIZED PROSTATE CANCER: COMPARISON OF INTERSTITIAL BRACHYTHERAPY VS. RADICAL PROSTATECTOMY (1999) (1)
Molecular Biomarkers of Response to PD-1/ PD-L1 Immune Checkpoint Blockade in Advanced Bladder Cancer1 (2019) (1)
Non-muscle Invasive Bladder Cancer Molecular Subtypes Predict Differential Response to Intravesical Bacillus Calmette-Guerin (2021) (1)
Pancreas Cancer Molecular Targets for Therapy (2011) (1)
Words of wisdom. Re: Phase II trial of cetuximab with or without paclitaxel in patients with advanced urothelial tract carcinoma. (2014) (1)
580: RalA and RalB: Antagonistic Relatives in Bladder Cancer Cell Migration (2005) (1)
KDM6A depletion in breast epithelial cells leads to reduced sensitivity to anticancer agents and increased TGF-β activity. (2022) (1)
Molecular Pathogenesis of Urothelial Carcinoma and the Development of Novel Therapeutic Strategies (2009) (1)
Molecular Pathogenesis of Bladder Cancer (2012) (1)
PtdIns 3-kinase (2011) (1)
Abstract P177: NPEPPS regulates cisplatin-resistance and can be targeted to overcome treatment resistance in patient-derived bladder cancer tumoroids (2021) (0)
[Metastatic dissemination of cancer cells]. (1991) (0)
P53, RB PROTEINS AND MICROVESSEL DENSITY ARE LONG TERM SURVIVAL MARKERS IN LOCALIZED CARCINOMA OF THE PROSTATE (1999) (0)
Population Candidate Gene Association Study (2011) (0)
Re: Mortality Results From the Goteborg Randomised Population-Based Prostate-Cancer Screening Trial Hugosson J, Carlsson S, Aus G, et al (2010) (0)
425: PTEN Inhibits Prostate Cancer Cell Migration in the Bone Microenvironment (2006) (0)
Abstract 5130: Src and Caveolin-1 reciprocally regulate metastasis via Rho Kinase (2010) (0)
MP59-09 CHARACTERIZING MOLECULAR SUBTYPES OF HIGH-RISK NON-MUSCLE-INVASIVE BLADDER CANCER IN AFRICAN AMERICAN PATIENTS (2022) (0)
Abstract 2700: In vitro-based COXEN biomarker model predicts outcome in metastatic colorectal cancer patients treated with cetuximab (2010) (0)
Bladder cancer global unbiased chromatin landscape characterization by DHS-seq to identify novel features unique for each stage of progression. (2014) (0)
Abstract 5063: Signatures of Ral GTPase status define key clinicopathologic characteristics and outcomes in cancer (2010) (0)
Results Disruption of FAK Expression in the Prostate of Normal and TRAMP Mice To assess the role of FAK in prostate cancer progression in TRAMP mice , normal and TRAMP mice were interbred (2009) (0)
ALTERNATIVE MEDICINE USE IN PATIENTS TREATED WITH CURATIVE INTENT FOR LOCALIZED PROSTATE CANCER (1999) (0)
YOUNG DENTISTS' AWARENESS OF CHANGES IN THE FACIAL SOFT TISSUES IN PATIENTS TREATED WITH EXTRACTION OF FOUR BICUSPIDS (2014) (0)
Abstract B11: Multi-omic interrogation of gemcitabine and cisplatin-resistant bladder cancer cell lines identifies unique and shared mediators of chemosensitivity and resistance (2020) (0)
New Sister Journal Kidney Cancer (2017) (0)
Abstract IA10: Developing rational combination therapy with checkpoint inhibitors (2020) (0)
VASCULAR ENDOTHELIAL GROWTH FACTOR IS TRANSCRIPTIONALLY REGULATED BY CELL DENSITY IN PROSTATE CANCER CELLS (1999) (0)
Dual tissue and plasma testing to improve detection of actionable variants in patients with solid cancers. (2022) (0)
AST-487 Inhibits RET Kinase Driven TERT Expression in Bladder Cancer (2022) (0)
Abstract 4085: DDR2 inhibition enhances response to anti-PD-1 immunotherapy (2019) (0)
Tumor and Host Determinants of Pulmonary Metastasis in Bladder Cancer (2011) (0)
PTEN is an inhibitor of prostate cancer cell migration in the bone microenvironment (2006) (0)
Targeting Glutamine Metabolism in Prostate Cancer. (2023) (0)
Abstract 2280: Endothelin axis in bladder cancer metastasis (2010) (0)
Characterizing molecular subtypes of high-risk nonmuscle-invasive bladder cancer in African American patients. (2022) (0)
Abstract 4200: Translation initiation factor eIF3b expression and its role in cancer cell growth and metastases (2012) (0)
Abstract A1-01: Translational genomics of urologic cancer genes (2015) (0)
Molecular determinants of chemotherapy response (2015) (0)
Erratum to: The UBC-40 Urothelial Bladder Cancer cell line index: a genomic resource for functional studies (2016) (0)
Author reply (2006) (0)
595: The Metastasis Suppressor Gene RhoGDI2 Reduceslung Metastasis in Human Bladder Cancer Via Downregulation of Endothelin 1 (2005) (0)
Preoperative magnetic resonance imaging for prostate cancer may be cost effective for men with a risk of extracapsular disease (2001) (0)
Abstract 2138: Tumorigenic and migratory potential of Ral GTPases in non-small cell lung cancers (2012) (0)
Erratum to: The UBC-40 Urothelial Bladder Cancer Cell Line Index: a genomic resource for functional studies (2015) (0)
PROSTATE SIZE AS A PREDICTOR OF PUBIC ARCH ACCESS IN BRACHYTHERAPY (2009) (0)
LBA03-09 CDH12 DRIVES THE DEVELOPMENT OF THE NEURONAL SUBTYPE IN MIBC (2023) (0)
Abstract SY36-01: Optimizing neoadjuvant therapy prior to surgery: Biomarker and target discovery (2017) (0)
Radiation exposure during computed tomography-guided cryoablation of renal masses. (2010) (0)
The faces and friends of RhoGDI2 (2012) (0)
Abstract 1105: Clinical associations between altered bladder cancer genes (2015) (0)
Aspects of Development and Progression of Bladder Cancer 2 (2019) (0)
Re: Genomic Differences Between "Primary" and "Secondary" Muscle-invasive Bladder Cancer as a Basis for Disparate Outcomes to Cisplatin-based Neoadjuvant Chemotherapy. (2019) (0)
Non-muscle invasive bladder cancer subtypes with differential response to intravesical bacillus Calmette-Guerin treatment (2022) (0)
Molecular and Cellular Pathobiology CD 24 Offers a Therapeutic Target for Control of Bladder Cancer Metastasis Based on a Requirement for Lung Colonization (2011) (0)
1371: Prospective Evaluation of the Clinical Relevance of Molecular Staging of Urothelial Bladder Carcinoma Following Radical Cystectomy (2005) (0)
Abstract 3082: A paradoxical suppressive role for Src in urothelial carcinoma (2010) (0)
Abstract 913: Differential roles of SPARC in bladder carcinogenesis and metastasis (2011) (0)
Clinical and Preclinical Therapies for Bladder Cancer Following Bacillus Calmette-Guérin Failure (2022) (0)
Genomancy: predicting tumor response to cancer therapy (2009) (0)
The UBC-40 Urothelial Bladder Cancer cell line index: a genomic resource for functional studies (2015) (0)
Abstract 747: Development and evaluation of rational combination therapy with imidazoacridinones for human bladder cancer patients through the COXEN algorithm (2010) (0)
642: Novel Prediction of Chemosensitivity in Urothelial Carcinoma by Transcriptional Profiling (2006) (0)
Abstract 615: Differential pathway analyses of BCG-treated T1HG bladder cancer using Philips OncoSignal: A pilot study (2021) (0)
635: CD24 is a Biomarker and Mediator For Urologic Neoplasia (2006) (0)
Genetic testing for metastasis: potential for improved cancer treatment. (2011) (0)
THE PHENOTYPIC AND CYTOGENETIC ANALYSIS OF T24T, A HIGHLY TUMORIGENIC SUBLINE OF THE HUMAN BLADDER CANCER CELL LINE T24 (1999) (0)
Prostate cancer--our patients' questions. (1996) (0)
Primary Cancer Site (2011) (0)
Cancer chemosensitivity prediction of drug combinations using single drug responses and microarray profiling data (2006) (0)
TheUBC-40UrothelialBladderCancercellline index:agenomicresourceforfunctionalstudies (2015) (0)
Abstract A52: Gene alterations associated with clinical characteristics of bladder cancer (2016) (0)
Chapter 35 – Personalized Medicine (2018) (0)
Urologists at Work THE HAUTMA" NEOBLADDER WITH A CHIMNEY: A VERSATILE MODIFICATION (1997) (0)
Abstract 5254: RNA extraction and gene expression profiling in circulating tumor cells (CTC) using a sized-based method for CTC capture (2011) (0)
POST-CYSTECTOMY UROLITHIASIS AMONG MEDICARE PATIENTS (2009) (0)
Abstract 614: Transcriptomic analysis of BCG-treated T1HG bladder cancer patients identifies an EMT-basal subgroup with immune suppressive characteristics at high risk of BCG-failure (2021) (0)
Identifying novel biomarkers associated with bladder cancer treatment outcomes (2023) (0)
Clinical Utility of Olaparib in the Treatment of Metastatic Castration-Resistant Prostate Cancer: A Review of Current Evidence and Patient Selection [Corrigendum] (2021) (0)
CLINICAL UROLOGY: Letters to the EditorsRe: Evaluation of Urinary Continence and Voiding Function: Early Results in Men With Neo-Urethral Modification of the Hautmann Orthotopic Neobladder (2002) (0)
High-Content Drug Discovery Targeting Molecular Bladder Cancer Subtypes (2022) (0)
Two methods of prediction signatures (2018) (0)
Transcriptional regulation in human bladder cancer cells by RalA and RalB via both independent and overlapping pathways (2006) (0)
Proteomic analysis of T24T derived bladder cancer cell lines using differential in-gel electrophoresis and LC-MS/MS (2007) (0)
Cancer esearch apeutics , Targets , and Chemical Biology sphorylation of RalB Is Important for Bladder Cancer R l Growth and Metastasis (2010) (0)
Transformation dependent signalling pathways leading to transcriptional induction of vascular endothelial growth factor in prostate cancer (2000) (0)
Abstract B102: Zibotentan (ZD4054), a specific antagonist of the endothelin A receptor, suppresses the metastatic phenotype of bladder cancer cells in vivo (2009) (0)
MP68-17 NOVEL INTRAVESICAL THERAPIES IDENTIFIED FROM HIGH THROUGHPUT SCREENING (2015) (0)
Transcriptome sequencing of BCG-treated T1HG bladder cancer patients identifies an EMT-basal subgroup with immune suppressive characteristics at high risk of BCG failure (2021) (0)
MP66-01 RNA-SEQUENCING OF BCG TREATED BLADDER CANCER PATIENTS IDENTIFIES PATIENTS WITH AGGRESSIVE AND IMMUNE SUPPRESSIVE TUMORS AT RISK OF BCG FAILURE (2021) (0)
Abstract 1140: CD24 exists in the nucleus and drives cancer growth (2016) (0)
Abstract 311: Phosphorylation of RalB by PKC regulates its intracellular distribution and promotion of bladder tumor growth (2010) (0)
Abstract 3391: Interaction of microRNAs and target genes in bladder cancer metastasis (2012) (0)
1316: Expression Mapping the Evolution of Human Metastatic Bladder Cancer (2005) (0)
Abstract 2899: Significance of microRNA:target interaction in bladder cancer metastasis. (2013) (0)
1181 BONE MORPHOGENETIC PROTEIN SIGNALING SUSTAINS PHOSPHATASE HOMOLOGUE OF TENSIN ANALOGUE PROTEIN EXPRESSION IN PROSTATE EPITHELIAL CELL LINES (2010) (0)
MP06-01 NON-MUSCLE INVASIVE BLADDER CANCER SUBTYPES WITH DIFFERENTIAL RESPONSE TO INTRAVESICAL BACILLUS CALMETTE-GUERIN TREATMENT (2022) (0)
Editorial (2004) (0)
Organ-sparing techniques for penile cancer: quo vadis? (2007) (0)
Abstract 3732: Drug signaling network-based prediction of therapeutic response to anti-cancer agents (2010) (0)
Precision Medicine in Bladder Cancer (2019) (0)
Cancer Metastasis: Bladder Cancer (2011) (0)
Abstract 2379: The importance of cell cycle biomarkers in prognostic signatures in tobacco-related cancers. (2013) (0)
Abstract 2996: The prognostic value of a cell cycle proliferation gene signature in bladder cancer (2012) (0)
Chapter 55 – Antioxidants and Phytotherapy (2003) (0)
Clinical and histopathological studies using fibrin-rich plasma in the treatment of bisphosphonate-related osteonecrosis of the jaw (2014) (0)
COMMENT ON : MOLECULAR DETERMINATION OF SURGICAL MARGINS USING FOSSA BIOPSIES AT RADICAL PROSTATECTOMY. AUTHORS' REPLY (1999) (0)
Abstract 4949: HAS2 is a critical effector for AGL mediated regulation of tumor growth (2015) (0)
A pilot clinical trial of genomic-based therapy assignment with co-expression extrapolation (COXEN) in advanced/metastatic urothelial carcinoma. (2021) (0)
Inhibition of the CCL2 receptor, CCR2, enhances tumor response to immune checkpoint therapy (2020) (0)
Editorial Comment: Prognostic Factors for Relapse in Stage I Testicular Seminoma Treated With Surveillance (1997) (0)
Human ColonCarcinomaFET CellsInVivoasRevealed byTransfection ofanAntisenseExpressionVector (1992) (0)
Abstract 2107: Integrative molecular and functional genomic analysis of chemotherapy resistant bladder cancer cell lines identifies novel mediators of therapeutic response (2019) (0)
Abstract 4091: Functional genomic screening in gemcitabine and cisplatin resistant bladder cancer cell lines identifies DNA repair pathways as mediators of chemosensitivity (2020) (0)
Abstract #1793: Comparison of gene expression and reverse-phase protein microarray profiling for prediction of chemosensitivity to lapatinib in human bladder cancer (2009) (0)
Letters to the EditorRE: MOLECULAR DETERMINATION OF SURGICAL MARGINS USING FOSSA BIOPSIES AT RADICAL PROSTATECTOMY (1999) (0)
213: Pelvic Cancer Incidence after Radiotherapy for Localized Prostate Cancer (2006) (0)
Gender Disparities in Bladder Cancer (2021) (0)
Abstract 449: Targeted proteomic analysis for personalized treatment of muscle invasive bladder cancer (2016) (0)
Molecular Nomograms for Predicting Prognosis and Treatment Response (2011) (0)
Major vault protein in bladder tumor drug resistance and cell signaling. (2006) (0)
Abstract 3090: RREB1 is necessary for the proliferation of bladder cancer cell lines (2010) (0)
1492: Atypical Small Acinar Proliferation (ASAP): A Distinct Diagnosis or Biopsy Artifact? (2006) (0)
A database of naturally occurring human urinary peptides and proteins for use in clinical applications (2007) (0)
Abstract 3352: Genome-wide enhancer identify signature predictive of metastatic phenotypes in bladder cancers (2017) (0)
Abstract 287: A SILAC proteomics analysis to identify bladder cancer metastasis-associated candidates (2011) (0)
Transforming Growth Factor 1 (TGFjJ1 ) Is an Autocrine Positive Regulator of Colon Carcinoma U9 Cells in Vivo as Shown by Transfection of a TGFI31 (1995) (0)
Words of wisdom. Re: mortality results from the Göteborg randomised population-based prostate-cancer screening trial. (2010) (0)
miRNAs associated with chemo-sensitivity in cell lines and in advanced bladder cancer (2012) (0)
The M 1 aminopeptidase NPEPPS is a 1 novel regulator of cisplatin sensitivity 2 3 (2021) (0)
High-performance detection of somatic D-loop mutation in urothelial cell carcinoma patients by polymorphism ratio sequencing (2016) (0)
Restitution du temple d'Aphrodite (1989) (0)
1357 BCG BLADDER TUMOR SUPPRESSION IS MEDIATED BY CXCR3 (2011) (0)
Abstract LB-65: A gene expression predictor of pathological node stage of urothelial bladder cancer (2010) (0)
764: Differential Expression of RAL GTPases and their Effectors in Bladder Cancer (2007) (0)
Assessment of Luminal and Basal Phenotypes in Bladder Cancer (2020) (0)
Abstract 5080: CD24 expression by prostate and bladder cancer cells is induced by hypoxia and promotes tumor growth and metastasis (2010) (0)
Sex differences in bladder cancer: emerging data and call to action (2022) (0)
Growth of Bladder and Breast Tumors Receptor Blockade Slows 2B Adenosine A (0)
[Physiopathology of the opening at the anastomosis following resection of the stomach]. (1958) (0)
A gene expression algorithm for the prediction of platinum sensitivity in ovarian cancer. (2010) (0)
IL10 Personalized Medicine and Drug Discovery in Urological Cancer (2010) (0)
Abstract 4782: Genome-wide chromatin profiling in bladder and prostate cancers (2015) (0)
1670: A New Approach for Predicting the Chemosensitivity of Human Cancers and its Application to Drug Discovery (2007) (0)
Molecular Credentialing of Rodent Bladder Carcinogenesis Models 1 (2014) (0)
role in t umor Gr owth of a Glycogen Debranching e nzyme l ost in Glycogen Storage Disease (2014) (0)
The origin of bladder cancer from mucosal field effects (2022) (0)
Contents: proteomics - clinical applications 4/2008. (2008) (0)

This paper list is powered by the following services:

Other Resources About Dan Theodorescu

en.wikipedia.org

What Schools Are Affiliated With Dan Theodorescu?

Dan Theodorescu is affiliated with the following schools: